Uncategorized

Passage launches strategic review and 75% layoffs after gene therapy path blocked by FDA

Published

on

After some tough feedback from the FDA on the path forward for its lead gene therapy, Passage Bio has launched a strategic review and set out a plan to whittle down its headcount by 75%.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version